

Alberto Albanese

List of Publications by Citations

Source: <https://exaly.com/author-pdf/5202537/alberto-albanese-publications-by-citations.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

334
papers

22,128
citations

68
h-index

142
g-index

365
ext. papers

24,944
ext. citations

6.2
avg. IF

6.3
L-index

#	Paper	IF	Citations
334	Hereditary early-onset Parkinson's disease caused by mutations in PINK1. <i>Science</i> , 2004 , 304, 1158-60	33.3	2586
333	Phenomenology and classification of dystonia: a consensus update. <i>Movement Disorders</i> , 2013 , 28, 863-73		1217
332	Consensus statement on the diagnosis of multiple system atrophy. <i>Journal of the Neurological Sciences</i> , 1999 , 163, 94-8	3.2	1006
331	Rivastigmine for dementia associated with Parkinson's disease. <i>New England Journal of Medicine</i> , 2004 , 351, 2509-18	59.2	919
330	Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up. <i>Brain</i> , 2005 , 128, 2240-9	11.2	837
329	PINK1 mutations are associated with sporadic early-onset parkinsonism. <i>Annals of Neurology</i> , 2004 , 56, 336-41	9.4	397
328	Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35-p36. <i>American Journal of Human Genetics</i> , 2001 , 68, 895-900	11	389
327	The impact of deep brain stimulation on executive function in Parkinson's disease. <i>Brain</i> , 2000 , 123 (Pt 6), 1142-54	11.2	376
326	The natural history of multiple system atrophy: a prospective European cohort study. <i>Lancet Neurology</i> , 2013 , 12, 264-74	24.1	322
325	Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease. <i>Movement Disorders</i> , 2010 , 25, 578-86	7	319
324	A comparison of injections of botulinum toxin and topical nitroglycerin ointment for the treatment of chronic anal fissure. <i>New England Journal of Medicine</i> , 1999 , 341, 65-9	59.2	317
323	Analysis of blink rate patterns in normal subjects. <i>Movement Disorders</i> , 1997 , 12, 1028-34	7	315
322	A comparison of botulinum toxin and saline for the treatment of chronic anal fissure. <i>New England Journal of Medicine</i> , 1998 , 338, 217-20	59.2	305
321	Motor and cognitive outcome in patients with Parkinson's disease 8 years after subthalamic implants. <i>Brain</i> , 2010 , 133, 2664-76	11.2	295
320	Levodopa in the treatment of Parkinson's disease: current controversies. <i>Movement Disorders</i> , 2004 , 19, 997-1005	7	291
319	Chronic subthalamic nucleus stimulation reduces medication requirements in Parkinson's disease. <i>Neurology</i> , 1999 , 53, 85-90	6.5	290
318	Treatment of motor and non-motor features of Parkinson's disease with deep brain stimulation. <i>Lancet Neurology</i> , 2012 , 11, 429-42	24.1	277

317	EFNS guidelines on diagnosis and treatment of primary dystonias. <i>European Journal of Neurology</i> , 2011 , 18, 5-18	6	277
316	Consensus statement on the diagnosis of multiple system atrophy. American Autonomic Society and American Academy of Neurology. <i>Clinical Autonomic Research</i> , 1998 , 8, 359-62	4.3	248
315	A systematic review on the diagnosis and treatment of primary (idiopathic) dystonia and dystonia plus syndromes: report of an EFNS/MDS-ES Task Force. <i>European Journal of Neurology</i> , 2006 , 13, 433-44	6	234
314	Transient mania with hypersexuality after surgery for high frequency stimulation of the subthalamic nucleus in Parkinson's disease. <i>Movement Disorders</i> , 2002 , 17, 1371-4	7	228
313	Pain as a nonmotor symptom of Parkinson disease: evidence from a case-control study. <i>Archives of Neurology</i> , 2008 , 65, 1191-4		186
312	White matter involvement in idiopathic Parkinson disease: a diffusion tensor imaging study. <i>American Journal of Neuroradiology</i> , 2009 , 30, 1222-6	4.4	184
311	Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. <i>Urology</i> , 2003 , 62, 259-64; discussion 264-5	1.6	181
310	Clinical and subclinical dopaminergic dysfunction in PARK6-linked parkinsonism: an 18F-dopa PET study. <i>Annals of Neurology</i> , 2002 , 52, 849-53	9.4	179
309	Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders. <i>Toxicon</i> , 2013 , 67, 94-114	2.8	171
308	Mitochondrial DNA haplogroup K is associated with a lower risk of Parkinson's disease in Italians. <i>European Journal of Human Genetics</i> , 2005 , 13, 748-52	5.3	169
307	Red flags for multiple system atrophy. <i>Movement Disorders</i> , 2008 , 23, 1093-9	7	168
306	Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study. <i>Lancet Neurology</i> , 2017 , 16, 701-711	24.1	161
305	Botulinum toxin for chronic anal fissure. <i>Lancet</i> , 1994 , 344, 1127-8	40	156
304	Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry. <i>Movement Disorders</i> , 2010 , 25, 2604-12	7	155
303	Long-term follow up of subthalamic nucleus stimulation in Parkinson's disease. <i>Neurology</i> , 2002 , 58, 1546-50		153
302	Cognitive and behavioural effects of chronic stimulation of the subthalamic nucleus in patients with Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2003 , 74, 175-82	5.5	152
301	Some specific clinical features differentiate multiple system atrophy (striatonigral variety) from Parkinson's disease. <i>Archives of Neurology</i> , 1995 , 52, 294-8		145
300	Primary dystonia and dystonia-plus syndromes: clinical characteristics, diagnosis, and pathogenesis. <i>Lancet Neurology</i> , 2011 , 10, 1074-85	24.1	144

299	Consensus statement on the diagnosis of multiple system atrophy. <i>Journal of the Autonomic Nervous System</i> , 1998 , 74, 189-92		132
298	Effectiveness of higher doses of botulinum toxin to induce healing in patients with chronic anal fissures. <i>Surgery</i> , 2002 , 131, 179-84	3.6	129
297	Safety and efficacy of botulinum toxin type A following long-term use. <i>European Journal of Neurology</i> , 2006 , 13 Suppl 4, 35-40	6	125
296	Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis. <i>European Journal of Neurology</i> , 2016 , 23, 45-52	6	119
295	Long-term effects of pallidal or subthalamic deep brain stimulation on quality of life in Parkinson's disease. <i>Movement Disorders</i> , 2009 , 24, 1154-61	7	114
294	Long-term outcome of subthalamic nucleus DBS in Parkinson's disease: from the advanced phase towards the late stage of the disease?. <i>Parkinsonism and Related Disorders</i> , 2014 , 20, 376-81	3.6	113
293	The diverse phenotype and genotype of pantothenate kinase-associated neurodegeneration. <i>Neurology</i> , 2005 , 64, 1810-2	6.5	111
292	Botulinum toxin injections in the internal anal sphincter for the treatment of chronic anal fissure: long-term results after two different dosage regimens. <i>Annals of Surgery</i> , 1998 , 228, 664-9	7.8	111
291	Influence of botulinum toxin site of injections on healing rate in patients with chronic anal fissure. <i>American Journal of Surgery</i> , 2000 , 179, 46-50	2.7	109
290	Aging is associated with a diffuse impairment of forebrain cholinergic neurons. <i>Brain Research</i> , 1990 , 508, 51-9	3.7	108
289	A genome-wide association study in multiple system atrophy. <i>Neurology</i> , 2016 , 87, 1591-1598	6.5	104
288	Dystonia rating scales: critique and recommendations. <i>Movement Disorders</i> , 2013 , 28, 874-83	7	103
287	Organization of the ascending projections from the ventral tegmental area: a multiple fluorescent retrograde tracer study in the rat. <i>Journal of Comparative Neurology</i> , 1983 , 216, 406-20	3.4	103
286	Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease: an evidence-based review. <i>Journal of Neurology</i> , 2013 , 260, 2701-14	5.5	102
285	Cognitive outcome 5 years after bilateral chronic stimulation of subthalamic nucleus in patients with Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007 , 78, 248-52	5.5	102
284	Zolpidem in Parkinson's disease. <i>Lancet, The</i> , 1997 , 349, 1222-3	40	99
283	Choline acetyltransferase (ChAT) activity differs in right and left human temporal lobes. <i>Neurology</i> , 1981 , 31, 799-805	6.5	99
282	Searching for the second best graft for coronary artery bypass surgery: a network meta-analysis of randomized controlled trials □ <i>European Journal of Cardio-thoracic Surgery</i> , 2015 , 47, 59-65; discussion 65	3	98

281	Efficacy of pallidal stimulation in isolated dystonia: a systematic review and meta-analysis. <i>European Journal of Neurology</i> , 2017 , 24, 552-560	6	97
280	Early DEtection of wEaring off in Parkinson disease: the DEEP study. <i>Parkinsonism and Related Disorders</i> , 2014 , 20, 204-11	3.6	90
279	Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease. <i>Movement Disorders</i> , 2001 , 16, 197-201	7	90
278	DYT13, a novel primary torsion dystonia locus, maps to chromosome 1p36.13B6.32 in an Italian family with cranial-cervical or upper limb onset. <i>Annals of Neurology</i> , 2001 , 49, 362-366	9.4	90
277	Evidence-based review and assessment of botulinum neurotoxin for the treatment of adult spasticity in the upper motor neuron syndrome. <i>Toxicon</i> , 2013 , 67, 115-28	2.8	89
276	Validation of the Italian version of the Movement Disorder Society--Unified Parkinson's Disease Rating Scale. <i>Neurological Sciences</i> , 2013 , 34, 683-7	3.5	85
275	Botulinum neurotoxins for post-stroke spasticity in adults: a systematic review. <i>Movement Disorders</i> , 2009 , 24, 801-12	7	83
274	Health-related quality of life in multiple system atrophy. <i>Movement Disorders</i> , 2006 , 21, 809-15	7	83
273	Bilateral contemporaneous posteroventral pallidotomy for the treatment of Parkinson's disease: neuropsychological and neurological side effects. Report of four cases and review of the literature. <i>Journal of Neurosurgery</i> , 1999 , 91, 313-21	3.2	83
272	Park6-linked parkinsonism occurs in several european families. <i>Annals of Neurology</i> , 2002 , 51, 14-18	9.4	81
271	Possible risk factors for primary adult onset dystonia: a case-control investigation by the Italian Movement Disorders Study Group. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1998 , 64, 25-32	5.5	81
270	The cortical projections of the thalamic intralaminar nuclei, as studied in cat and rat with the multiple fluorescent retrograde tracing technique. <i>Neuroscience Letters</i> , 1981 , 26, 5-10	3.3	79
269	Levodopa in the treatment of Parkinson's disease: a consensus meeting. <i>Movement Disorders</i> , 1999 , 14, 911-3	7	78
268	Excessive daytime sleepiness in multiple system atrophy (SLEEMSA study). <i>Archives of Neurology</i> , 2011 , 68, 223-30		73
267	The PINK1 phenotype can be indistinguishable from idiopathic Parkinson disease. <i>Neurology</i> , 2005 , 64, 1958-60	6.5	73
266	Severe constipation in Parkinson's disease relieved by botulinum toxin. <i>Movement Disorders</i> , 1997 , 12, 764-6	7	67
265	The European Multiple System Atrophy-Study Group (EMSA-SG). <i>Journal of Neural Transmission</i> , 2005 , 112, 1677-86	4.3	63
264	Replacement of dopaminergic medication with subthalamic nucleus stimulation in Parkinson's disease: long-term observation. <i>Movement Disorders</i> , 2009 , 24, 557-63	7	60

263	Clinical usefulness of apomorphine in movement disorders. <i>Clinical Neuropharmacology</i> , 1994 , 17, 243-59.	4	60
262	Suicidal ideation in a European Huntington's disease population. <i>Journal of Affective Disorders</i> , 2013 , 151, 248-58	6.6	59
261	Botulinum toxin in the treatment of outlet obstruction constipation caused by puborectalis syndrome. <i>Diseases of the Colon and Rectum</i> , 2000 , 43, 376-80	3.1	59
260	Impulse control behaviours in patients with Parkinson's disease after subthalamic deep brain stimulation: de novo cases and 3-year follow-up. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015 , 86, 562-4	5.5	58
259	PINK1 heterozygous rare variants: prevalence, significance and phenotypic spectrum. <i>Human Mutation</i> , 2008 , 29, 565	4.7	58
258	The clinical expression of primary dystonia. <i>Journal of Neurology</i> , 2003 , 250, 1145-51	5.5	58
257	Treatable inherited rare movement disorders. <i>Movement Disorders</i> , 2018 , 33, 21-35	7	57
256	Is this dystonia?. <i>Movement Disorders</i> , 2009 , 24, 1725-31	7	57
255	Synergistic control of protein kinase Cgamma activity by ionotropic and metabotropic glutamate receptor inputs in hippocampal neurons. <i>Journal of Neuroscience</i> , 2006 , 26, 3404-11	6.6	57
254	Phenotypic characterisation of autosomal recessive PARK6-linked parkinsonism in three unrelated Italian families. <i>Movement Disorders</i> , 2001 , 16, 999-1006	7	57
253	Bladder hyperreflexia induced in marmosets by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. <i>Neuroscience Letters</i> , 1988 , 87, 46-50	3.3	56
252	Acetylcholinesterase and catecholamine distribution in the locus ceruleus of the rat. <i>Brain Research Bulletin</i> , 1980 , 5, 127-34	3.9	56
251	Treatment of outlet obstruction constipation in Parkinson's disease with botulinum neurotoxin A. <i>American Journal of Gastroenterology</i> , 2003 , 98, 1439-40	0.7	54
250	Levodopa-induced dyskinesias and their management. <i>Journal of Neurology</i> , 2008 , 255 Suppl 4, 32-41	5.5	53
249	Botulinum neurotoxin to treat chronic anal fissure: results of a randomized "Botox vs. Dysport" controlled trial. <i>Alimentary Pharmacology and Therapeutics</i> , 2004 , 19, 695-701	6.1	53
248	Multiple system atrophy presenting as parkinsonism: clinical features and diagnostic criteria. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1995 , 59, 144-51	5.5	53
247	Treatment of essential tremor: a systematic review of evidence and recommendations from the Italian Movement Disorders Association. <i>Journal of Neurology</i> , 2013 , 260, 714-40	5.5	52
246	Terminology for preparations of botulinum neurotoxins: what a difference a name makes. <i>JAMA - Journal of the American Medical Association</i> , 2011 , 305, 89-90	27.4	51

245	Conflict-dependent dynamic of subthalamic nucleus oscillations during moral decisions. <i>Social Neuroscience</i> , 2011 , 6, 243-56	2	50
244	Fifteen-year experience in treating blepharospasm with Botox or Dysport: same toxin, two drugs. <i>Neurotoxicity Research</i> , 2009 , 15, 224-31	4.3	50
243	Abnormal tactile temporal discrimination in psychogenic dystonia. <i>Neurology</i> , 2011 , 77, 1191-7	6.5	50
242	Acute challenge with apomorphine and levodopa in Parkinsonism. <i>European Neurology</i> , 2000 , 43, 95-101	2.1	50
241	Risk factors for spread of primary adult onset blepharospasm: a multicentre investigation of the Italian movement disorders study group. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1999 , 67, 613-9	5.5	49
240	Chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to monkeys: behavioural, morphological and biochemical correlates. <i>Neuroscience</i> , 1993 , 55, 823-32	3.9	49
239	Inclusion and exclusion criteria for DBS in dystonia. <i>Movement Disorders</i> , 2011 , 26 Suppl 1, S5-16	7	48
238	Surgical treatment of Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 1999 , 167, 1-10	3.2	46
237	Age-dependent loss of cholinergic neurones in basal ganglia of rats. <i>Brain Research</i> , 1988 , 455, 177-81	3.7	46
236	Mitochondrial dysfunction in Parkinson disease: evidence in mutant PARK2 fibroblasts. <i>Frontiers in Genetics</i> , 2015 , 6, 78	4.5	45
235	Pallidal stimulation for acquired dystonia due to cerebral palsy: beyond 5 years. <i>European Journal of Neurology</i> , 2015 , 22, 426-e32	6	45
234	Substantia nigra in Parkinson's disease: a multimodal MRI comparison between early and advanced stages of the disease. <i>Neurological Sciences</i> , 2014 , 35, 753-8	3.5	45
233	In vivo evidence for GABA(A) receptor changes in the sensorimotor system in primary dystonia. <i>Movement Disorders</i> , 2011 , 26, 852-7	7	45
232	The diagnostic challenge of primary dystonia: evidence from misdiagnosis. <i>Movement Disorders</i> , 2010 , 25, 1619-26	7	45
231	Clinical Practice: Evidence-Based Recommendations for the Treatment of Cervical Dystonia with Botulinum Toxin. <i>Frontiers in Neurology</i> , 2017 , 8, 35	4.1	43
230	Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement. <i>Journal of Neurology</i> , 2015 , 262, 2201-13	5.5	42
229	Further treatment with MPTP does not produce parkinsonism in marmosets showing behavioural recovery from motor deficits induced by an earlier exposure to the toxin. <i>Neuropharmacology</i> , 1989 , 28, 1089-97	5.5	42
228	The organization of dopaminergic and non-dopaminergic mesencephalo-cortical neurons in the rat. <i>Brain Research</i> , 1982 , 238, 421-5	3.7	42

227	Botulinum toxin injected in the gastric wall reduces body weight and food intake in rats. <i>Alimentary Pharmacology and Therapeutics</i> , 2000 , 14, 829-34	6.1	41
226	Pretarsal injections of botulinum toxin improve blepharospasm in previously unresponsive patients. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1996 , 60, 693-4	5.5	40
225	Locus ceruleus somata contain both acetylcholin esterase and norepinephrine: direct histochemical demonstration on the same tissue section. <i>Neuroscience Letters</i> , 1979 , 14, 101-4	3.3	40
224	Relief by botulinum toxin of voiding dysfunction due to prostatitis. <i>Lancet, The</i> , 1998 , 352, 625	4.0	39
223	Effects of stimulation of the subthalamic nucleus on naming and reading nouns and verbs in Parkinson's disease. <i>Neuropsychologia</i> , 2012 , 50, 1980-9	3.2	38
222	Pathological gambling in Parkinson's disease: subthalamic oscillations during economics decisions. <i>Movement Disorders</i> , 2013 , 28, 1644-52	7	38
221	Dystonia: diagnosis and management. <i>European Journal of Neurology</i> , 2019 , 26, 5-17	6	37
220	Analysis of blink rate in patients with blepharospasm. <i>Movement Disorders</i> , 2006 , 21, 1225-9	7	37
219	Fixed dystonia unresponsive to pallidal stimulation improved by motor cortex stimulation. <i>Neurology</i> , 2007 , 68, 875-6	6.5	37
218	Primary torsion dystonia: the search for genes is not over. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1999 , 67, 395-7	5.5	37
217	Botulinum toxin as a treatment for blepharospasm, spasmodic torticollis and hemifacial spasm. <i>European Neurology</i> , 1992 , 32, 112-7	2.1	37
216	Mutation screening of the DYT6/THAP1 gene in Italy. <i>Movement Disorders</i> , 2009 , 24, 2424-7	7	36
215	Disability and profiles of functioning of patients with Parkinson's disease described with ICF classification. <i>International Journal of Rehabilitation Research</i> , 2011 , 34, 141-50	1.8	36
214	Review article: the use of botulinum toxin in the alimentary tract. <i>Alimentary Pharmacology and Therapeutics</i> , 1995 , 9, 599-604	6.1	36
213	Non-motor effects of deep brain stimulation of the subthalamic nucleus in Parkinson's disease: preliminary physiological results. <i>Neurological Sciences</i> , 2001 , 22, 85-6	3.5	36
212	Genome-wide association study in musician's dystonia: a risk variant at the arylsulfatase G locus?. <i>Movement Disorders</i> , 2014 , 29, 921-7	7	35
211	Strain-dependent variations in the number of forebrain cholinergic neurons. <i>Brain Research</i> , 1985 , 334, 380-4	3.7	35
210	Cholinergic and non-cholinergic forebrain projections to the interpeduncular nucleus. <i>Brain Research</i> , 1985 , 329, 334-9	3.7	35

209	GBA-Related Parkinson's Disease: Dissection of Genotype-Phenotype Correlates in a Large Italian Cohort. <i>Movement Disorders</i> , 2020 , 35, 2106-2111	7	35
208	Deep brain stimulation for movement disorders. Considerations on 276 consecutive patients. <i>Journal of Neural Transmission</i> , 2011 , 118, 1497-510	4.3	34
207	Clinical and neuropsychological correlates in two brothers with pantothenate kinase-associated neurodegeneration. <i>Movement Disorders</i> , 2005 , 20, 208-12	7	34
206	Outcome predictors, efficacy and safety of Botox and Dysport in the long-term treatment of hemifacial spasm. <i>European Journal of Neurology</i> , 2009 , 16, 392-8	6	33
205	Progression of dysautonomia in multiple system atrophy: a prospective study of self-perceived impairment. <i>European Journal of Neurology</i> , 2007 , 14, 66-72	6	33
204	Olfactory dysfunction in Parkinsonism caused by PINK1 mutations. <i>Movement Disorders</i> , 2009 , 24, 2350-7	7	32
203	A neurophysiological study of myoclonus in patients with DYT11 myoclonus-dystonia syndrome. <i>Movement Disorders</i> , 2008 , 23, 2041-8	7	32
202	Non-DYT1 early-onset primary torsion dystonia: comparison with DYT1 phenotype and review of the literature. <i>Movement Disorders</i> , 2006 , 21, 1411-8	7	32
201	High frequency stimulation of the subthalamic nucleus is efficacious in Parkin disease. <i>Journal of Neurology</i> , 2005 , 252, 208-11	5.5	32
200	Results by motor cortex stimulation in treatment of focal dystonia, Parkinson's disease and post-ictal spasticity. The experience of the Italian Study Group of the Italian Neurosurgical Society. <i>Acta Neurochirurgica Supplementum</i> , 2008 , 101, 13-21	1.7	32
199	Causes of withdrawal of duodenal levodopa infusion in advanced Parkinson disease. <i>Neurology</i> , 2015 , 84, 1669-72	6.5	31
198	Minimally invasive direct coronary artery bypass improves late survival compared with drug-eluting stents in isolated proximal left anterior descending artery disease: a 10-year follow-up, single-center, propensity score analysis. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2014 , 148, 1316-22	1.5	31
197	Cognitive decline in Huntington's disease expansion gene carriers. <i>Cortex</i> , 2017 , 95, 51-62	3.8	31
196	Relationships between disability, quality of life and prevalence of nonmotor symptoms in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2012 , 18, 35-9	3.6	31
195	Bilateral high frequency subthalamic stimulation in Parkinson's disease: long-term neurological follow-up. <i>Journal of Neurosurgical Sciences</i> , 2003 , 47, 119-28	1.3	31
194	Non-DYT1 dystonia in a large Italian family. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1997 , 62, 357-60	5.5	30
193	Phenotypic characterization of DYT13 primary torsion dystonia. <i>Movement Disorders</i> , 2004 , 19, 200-6	7	30
192	Spontaneous neuronal activity of the posterior hypothalamus in trigeminal autonomic cephalalgias. <i>Neurological Sciences</i> , 2007 , 28, 93-5	3.5	29

191	Phenotypic variability of DYT1-PTD: does the clinical spectrum include psychogenic dystonia?. <i>Movement Disorders</i> , 2002 , 17, 1058-63	7	29
190	Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial. <i>Lancet Neurology</i> , 2021 , 20, 182-192	24.1	29
189	The New Classification System for the Dystonias: Why Was it Needed and How was it Developed?. <i>Movement Disorders Clinical Practice</i> , 2014 , 1, 280-284	2.2	28
188	Subclinical sensory abnormalities in unaffected PINK1 heterozygotes. <i>Journal of Neurology</i> , 2008 , 255, 1372-7	5.5	28
187	Progressive supranuclear palsy and Parkinson's disease in a family with a new mutation in the tau gene. <i>Annals of Neurology</i> , 2004 , 55, 448	9.4	28
186	PARK6 is a common cause of familial parkinsonism. <i>Neurological Sciences</i> , 2002 , 23 Suppl 2, S117-8	3.5	27
185	Anterior rectocele due to obstructed defecation relieved by botulinum toxin. <i>Surgery</i> , 2001 , 129, 524-9	3.6	27
184	Monoamine oxidase activity and distribution in marmoset brain: implications for MPTP toxicity. <i>Neuroscience Letters</i> , 1988 , 90, 100-6	3.3	27
183	Expert recommendations for diagnosing cervical, oromandibular, and limb dystonia. <i>Neurological Sciences</i> , 2019 , 40, 89-95	3.5	27
182	A case of dementia parkinsonism resembling progressive supranuclear palsy due to mutation in the tau protein gene. <i>Archives of Neurology</i> , 2003 , 60, 1454-6		26
181	Targeting the brain: considerations in 332 consecutive patients treated by deep brain stimulation (DBS) for severe neurological diseases. <i>Neurological Sciences</i> , 2012 , 33, 1285-303	3.5	25
180	Dopaminergic therapy and subthalamic stimulation in Parkinson's disease: a review of 5-year reports. <i>Journal of Neurology</i> , 2010 , 257, S298-304	5.5	25
179	Abnormal gating of somatosensory inputs in essential tremor. <i>Clinical Neurophysiology</i> , 2003 , 114, 120-9	4.3	25
178	Update on dystonia. <i>Current Opinion in Neurology</i> , 2012 , 25, 483-90	7.1	23
177	Organization of central nervous system dopaminergic pathways. <i>Journal of Neural Transmission Supplementum</i> , 1986 , 22, 3-17		23
176	Dystonia and Tremor: The Clinical Syndromes with Isolated Tremor. <i>Tremor and Other Hyperkinetic Movements</i> , 2020 , 6, 319	2	23
175	The Italian Dystonia Registry: rationale, design and preliminary findings. <i>Neurological Sciences</i> , 2017 , 38, 819-825	3.5	22
174	Epidural premotor cortical stimulation in primary focal dystonia: clinical and 18F-fluoro deoxyglucose positron emission tomography open study. <i>Movement Disorders</i> , 2012 , 27, 533-8	7	22

173	Alpha-synuclein gene duplication: marked intrafamilial variability in two novel pedigrees. <i>Movement Disorders</i> , 2013 , 28, 813-7	7	22
172	Clinical management of pain and fatigue in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2012 , 18 Suppl 1, S233-6	3.6	22
171	Mood disorder following DBS of the left amygdaloid region in a dystonia patient with a dislodged electrode. <i>Movement Disorders</i> , 2008 , 23, 147-50	7	22
170	Role of the dopamine D5 receptor (DRD5) as a susceptibility gene for cervical dystonia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2003 , 74, 665-6	5.5	22
169	Suicide after successful deep brain stimulation for movement disorders. <i>Neurology</i> , 2005 , 65, 499-500; author reply 499-500	6.5	22
168	Italian family with cranial cervical dystonia: clinical and genetic study. <i>Movement Disorders</i> , 1999 , 14, 820-5	7	22
167	Motor features and response to oral levodopa in patients with Parkinson's disease under continuous dopaminergic infusion or deep brain stimulation. <i>European Journal of Neurology</i> , 2012 , 19, 76-83	6	21
166	Treatment with botulinum neurotoxin of gastrointestinal smooth muscles and sphincters spasms. <i>Movement Disorders</i> , 2004 , 19 Suppl 8, S146-56	7	21
165	Management of cervical dystonia with botulinum neurotoxins and EMG/ultrasound guidance. <i>Neurology: Clinical Practice</i> , 2019 , 9, 64-73	1.7	21
164	Obsessive-compulsive behaviour and cognitive impairment in a parkinsonian patient after left putaminal lesion. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1997 , 62, 288-9	5.5	20
163	Surgery of Parkinson's disease: inclusion criteria and follow-up. <i>Neurological Sciences</i> , 2003 , 24 Suppl 1, S38-40	3.5	20
162	Clinical Correlates of Functional Motor Disorders: An Italian Multicenter Study. <i>Movement Disorders Clinical Practice</i> , 2020 , 7, 920-929	2.2	20
161	Transient gender-related effects in Parkinson's disease patients with subthalamic stimulation. <i>Journal of Neurology</i> , 2010 , 257, 603-8	5.5	19
160	Impaired body movement representation in DYT1 mutation carriers. <i>Clinical Neurophysiology</i> , 2008 , 119, 1864-1869	4.3	19
159	Tardive lingual dystonia treated with clozapine. <i>Movement Disorders</i> , 1996 , 11, 585-6	7	19
158	Mitochondrial dysfunction in fibroblasts of Multiple System Atrophy. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018 , 1864, 3588-3597	6.9	19
157	Therapeutic advances in dystonia. <i>Movement Disorders</i> , 2015 , 30, 1547-56	7	18
156	Frequency and phenotypes of LRRK2 G2019S mutation in Italian patients with Parkinson's disease. <i>Movement Disorders</i> , 2006 , 21, 1232-5	7	18

155	Severe barbiturate withdrawal syndrome in migrainous patients. <i>Headache</i> , 1996 , 36, 119-21	4.2	18
154	Genetically determined cholinergic deficiency in the forebrain of C57BL/6 mice. <i>Brain Research</i> , 1994 , 637, 181-9	3.7	18
153	NMDA receptor gene variations as modifiers in Huntington disease: a replication study. <i>PLOS Currents</i> , 2011 , 3, RRN1247		18
152	Quantitative gait analysis in parkin disease: Possible role of dystonia. <i>Movement Disorders</i> , 2016 , 31, 1720-1728		17
151	Cortical myoclonus in childhood and juvenile onset Huntington's disease. <i>Parkinsonism and Related Disorders</i> , 2012 , 18, 794-7	3.6	17
150	Functioning and disability in Parkinson's disease. <i>Disability and Rehabilitation</i> , 2010 , 32 Suppl 1, S33-41	2.4	17
149	Gastrointestinal smooth muscles and sphincters spasms: treatment with botulinum neurotoxin. <i>Current Medicinal Chemistry</i> , 2003 , 10, 603-23	4.3	17
148	Retrograde fluorescent neuronal tracing combined with acetylcholinesterase histochemistry. <i>Journal of Neuroscience Methods</i> , 1982 , 6, 121-7	3	17
147	Isolated limb dystonia as presenting feature of Parkin disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014 , 85, 827-8	5.5	16
146	Botulinum toxin for the management of adult patients with upper motor neuron syndrome. <i>Toxicon</i> , 2009 , 54, 634-8	2.8	16
145	Discrepancies in reporting the CAG repeat lengths for Huntington's disease. <i>European Journal of Human Genetics</i> , 2012 , 20, 20-6	5.3	16
144	Cognitive and psychiatric characterization of patients with Huntington's disease and their at-risk relatives. <i>Neurological Sciences</i> , 2002 , 23 Suppl 2, S105-6	3.5	16
143	Clozapine in Huntington's disease. <i>Neurology</i> , 1995 , 45, 1023-4	6.5	16
142	Acute administration of individual optimal dose of physostigmine fails to improve mnemonic performances in Alzheimers Presenile Dementia. <i>International Journal of Neuroscience</i> , 1983 , 18, 143-7	2	16
141	Neurological features in SARS-CoV-2-infected patients with smell and taste disorder. <i>Journal of Neurology</i> , 2021 , 268, 1570-1572	5.5	16
140	Idiopathic delayed-onset edema surrounding deep brain stimulation leads: Insights from a case series and systematic literature review. <i>Parkinsonism and Related Disorders</i> , 2016 , 32, 108-115	3.6	15
139	Smoking cessation before coronary artery bypass grafting improves operative outcomes. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2014 , 148, 468-74	1.5	15
138	Differential diagnosis of dystonia. <i>European Journal of Neurology</i> , 2010 , 17 Suppl 1, 1-8	6	15

137	Diagnostic criteria for Parkinson's disease. <i>Neurological Sciences</i> , 2003 , 24 Suppl 1, S23-6	3.5	15
136	Identification of a novel primary torsion dystonia locus (DYT13) on chromosome 1p36 in an Italian family with cranial-cervical or upper limb onset. <i>Neurological Sciences</i> , 2001 , 22, 95-6	3.5	15
135	Acute challenge with apomorphine in Huntington's disease: a double-blind study. <i>Clinical Neuropharmacology</i> , 1995 , 18, 427-34	1.4	15
134	Peripheral neuropathy in the course of progressive systemic sclerosis: light and ultrastructural study. <i>Italian Journal of Neurological Sciences</i> , 1982 , 3, 341-8		15
133	Dystonia and Tremor: The Clinical Syndromes with Isolated Tremor. <i>Tremor and Other Hyperkinetic Movements</i> , 2016 , 6, 319	2	15
132	Axial motor clues to identify atypical parkinsonism: A multicentre European cohort study. <i>Parkinsonism and Related Disorders</i> , 2018 , 56, 33-40	3.6	14
131	Designing clinical trials for dystonia. <i>Neurotherapeutics</i> , 2014 , 11, 117-27	6.4	14
130	How Many Dystonias? Clinical Evidence. <i>Frontiers in Neurology</i> , 2017 , 8, 18	4.1	14
129	Pre-operative evaluations for DBS in dystonia. <i>Movement Disorders</i> , 2011 , 26 Suppl 1, S17-22	7	14
128	Onset and progression of primary torsion dystonia in sporadic and familial cases. <i>European Journal of Neurology</i> , 2006 , 13, 1083-8	6	14
127	Functional motor disorders associated with other neurological diseases: Beyond the boundaries of "organic" neurology. <i>European Journal of Neurology</i> , 2021 , 28, 1752-1758	6	14
126	Failure of pallidal deep brain stimulation in DYT12-ATP1A3 dystonia. <i>Parkinsonism and Related Disorders</i> , 2017 , 45, 99-100	3.6	13
125	A study of arm movements in Huntington's disease under visually controlled and blindfolded conditions. <i>Neurological Sciences</i> , 2003 , 23, 287-93	3.5	13
124	Idiopathic Non-task-Specific Upper Limb Dystonia, a Neglected Form of Dystonia. <i>Movement Disorders</i> , 2020 , 35, 2038-2045	7	13
123	Functional motor phenotypes: to lump or to split?. <i>Journal of Neurology</i> , 2021 , 268, 4737-4743	5.5	13
122	Long-term ventralis intermedius thalamic stimulation for parkinsonian tremor. Italian Registry for Neuromodulation in Movement Disorders. <i>Advances in Neurology</i> , 1999 , 80, 631-4		13
121	Quantitative pharmacohistochemistry of acetylcholinesterase in neostriatum of inbred strains of mice. <i>Brain Research</i> , 1986 , 374, 402-8	3.7	12
120	DYT13, a novel primary torsion dystonia locus, maps to chromosome 1p36.13--36.32 in an Italian family with cranial-cervical or upper limb onset. <i>Annals of Neurology</i> , 2001 , 49, 362-6	9.4	12

119	Impact of nonmotor symptoms on disability in patients with Parkinson's disease. <i>International Journal of Rehabilitation Research</i> , 2011 , 34, 316-20	1.8	11
118	Dystonia: clinical approach. <i>Parkinsonism and Related Disorders</i> , 2007 , 13 Suppl 3, S356-61	3.6	11
117	Can trazodone induce parkinsonism?. <i>Clinical Neuropharmacology</i> , 1988 , 11, 180-2	1.4	11
116	Clinical Reasoning: A case of COVID-19-associated pharyngeal-cervical-brachial variant of Guillain-Barré syndrome. <i>Neurology</i> , 2020 , 95, 978-983	6.5	11
115	Demographic and clinical determinants of neck pain in idiopathic cervical dystonia. <i>Journal of Neural Transmission</i> , 2020 , 127, 1435-1439	4.3	11
114	Recent developments in clinical trials of botulinum neurotoxins. <i>Toxicon</i> , 2018 , 147, 77-83	2.8	11
113	Does acute peripheral trauma contribute to idiopathic adult-onset dystonia?. <i>Parkinsonism and Related Disorders</i> , 2020 , 71, 40-43	3.6	10
112	Low-voltage bilateral pallidal stimulation for severe meige syndrome in a patient with primary segmental dystonia: case report. <i>Operative Neurosurgery</i> , 2010 , 67, onsE308; discussion onsE308	1.6	10
111	Phenotype variability of dystonia in monozygotic twins. <i>Journal of Neurology</i> , 2000 , 247, 148-50	5.5	10
110	Botulinum neurotoxins for the treatment of focal dystonias: Review of rating tools used in clinical trials. <i>Toxicon</i> , 2015 , 107, 89-97	2.8	9
109	Quality and reporting of guidelines on the diagnosis and management of dystonia. <i>European Journal of Neurology</i> , 2018 , 25, 275-283	6	9
108	Choice-option evaluation is preserved in early Huntington and Parkinson's disease. <i>NeuroReport</i> , 2011 , 22, 753-7	1.7	9
107	Behavioral and personality features in patients with lateralized Parkinson's disease. <i>European Journal of Neurology</i> , 2011 , 18, 772-7	6	9
106	Primary focal hyperhidrosis in a new family not linked to known loci. <i>Dermatology</i> , 2011 , 223, 335-42	4.4	9
105	A multicenter Italian randomised study on early treatment of Parkinson disease: comparison of L-dopa, l-deprenyl and dopaminoagonists. Study design and short term results. The Italian Parkinson Study Group. <i>Italian Journal of Neurological Sciences</i> , 1992 , 13, 735-9		9
104	Postural axial tremor in a patient with cerebellar atrophy. <i>Movement Disorders</i> , 1992 , 7, 273-80	7	9
103	Botulinum toxin in motor disorders. <i>Current Opinion in Neurology</i> , 1999 , 12, 447-56	7.1	9
102	Concordance between severity of disease, prevalence of nonmotor symptoms, patient-reported quality of life and disability and use of medication in Parkinson's disease. <i>Neurological Sciences</i> , 2012 , 33, 847-53	3.5	8

101	Distinguishing scan without evidence of dopaminergic depletion patients with asymmetric resting tremor from Parkinson's disease: a clinical diagnosis of dystonia is required. <i>Movement Disorders</i> , 2010 , 25, 2899	7	8
100	Normal cardiovascular reflex testing in patients with parkin disease. <i>Movement Disorders</i> , 2007 , 22, 528-32		8
99	Management of bladder, prostatic and pelvic floor disorders. <i>Neurotoxicity Research</i> , 2006 , 9, 161-72	4.3	8
98	Chronic administration of MPTP to monkeys: behavioural morphological and biochemical correlates. <i>Neurochemistry International</i> , 1992 , 20 Suppl, 279S-285S	4.4	8
97	Shifting from constant-voltage to constant-current in Parkinson's disease patients with chronic stimulation. <i>Neurological Sciences</i> , 2017 , 38, 1505-1508	3.5	7
96	Subthalamic involvement in monetary reward and its dysfunction in parkinsonian gamblers. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015 , 86, 355-8	5.5	7
95	Attentional Networks in Parkinson's Disease. <i>Behavioural Neurology</i> , 2013 , 27, 495-500	3	7
94	Extrapyramidal system, motor Ganglia and movement disorders. <i>Reviews in the Neurosciences</i> , 1990 , 2, 145-64	4.7	7
93	VPS35-Based Approach: A Potential Innovative Treatment in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2019 , 10, 1272	4.1	7
92	Clinical guidelines: No more mistaken identities for botulinum neurotoxins. <i>Nature Reviews Neurology</i> , 2016 , 12, 373-4	15	6
91	Deep brain stimulation for Parkinson's disease: where do we stand?. <i>Frontiers in Neurology</i> , 2011 , 2, 33	4.1	6
90	Rivastigmine in Parkinson's disease dementia. <i>Expert Review of Neurotherapeutics</i> , 2008 , 8, 1181-8	4.3	6
89	Histochemical demonstration of heavy metals in the reptilian archicortex. <i>International Journal of Neuroscience</i> , 1985 , 28, 11-9	2	6
88	Deep brain stimulation for cervical dystonia. <i>Lancet Neurology</i> , 2014 , 13, 856-7	24.1	5
87	Ambiguous idiom processing in Parkinson's disease patients. <i>Cognitive Neuropsychology</i> , 2013 , 30, 495-506		5
86	Discussion of unique properties of botulinum toxins. <i>Toxicon</i> , 2009 , 54, 702-8	2.8	5
85	Emerging treatments in Parkinson's disease. <i>European Neurology</i> , 1997 , 38, 175-83	2.1	5
84	Fixed dystonia unresponsive to pallidal stimulation improved by motor cortex stimulation. <i>Neurology</i> , 2007 , 69, 1062-3; author reply 1063	6.5	5

83	Oligophrenia with the Hallermann-Streiff syndrome. <i>Journal of Neurology</i> , 1979 , 220, 211-4	5.5	5
82	A genetic study of neostriatal cholinergic neurones in C57BL/6 and DBA/2 mice. <i>Functional Neurology</i> , 1987 , 2, 273-9	2.2	5
81	Advances in the genetics of primary torsion dystonia. <i>F1000 Biology Reports</i> , 2010 , 2,		5
80	Management of dystonia in Europe: a survey of the European network for the study of the dystonia syndromes. <i>European Journal of Neurology</i> , 2016 , 23, 772-9	6	5
79	Dihydroergocriptine in Parkinson's disease: clinical efficacy and comparison with other dopamine agonists. <i>Acta Neurologica Scandinavica</i> , 2003 , 107, 349-55	3.8	4
78	Unsuspected, surreptitious drug-induced parkinsonism. <i>Neurology</i> , 1992 , 42, 459	6.5	4
77	"Complex" dystonia is not a category in the new 2013 consensus classification. <i>Movement Disorders</i> , 2016 , 31, 1758-1759	7	4
76	Adapting to post-COVID19 research in Parkinson's disease: Lessons from a multinational experience. <i>Parkinsonism and Related Disorders</i> , 2021 , 82, 146-149	3.6	4
75	The clinical diagnosis of multiple system atrophy presenting as pure parkinsonism. <i>Advances in Neurology</i> , 1996 , 69, 393-8		4
74	Clinical presentation and progression of sporadic and familial primary torsion dystonia in Italy. <i>Advances in Neurology</i> , 2004 , 94, 171-8		4
73	Gabapentin improved sensory and motor symptoms in the restless legs syndrome. <i>ACP Journal Club</i> , 2003 , 139, 17		4
72	Reliability and validity of the range of motion scale (ROMS) in patients with abnormal postures. <i>Pain Medicine</i> , 2015 , 16, 488-93	2.8	3
71	Design and Operation of the Lombardy Parkinson's Disease Network. <i>Frontiers in Neurology</i> , 2020 , 11, 573	4.1	3
70	Cell therapy for Parkinson's disease: have the glory days gone?. <i>Lancet Neurology</i> , 2011 , 10, 492-3	24.1	3
69	Emerging parkinsonian phenotypes. <i>Revue Neurologique</i> , 2010 , 166, 834-40	3	3
68	Unique properties of botulinum toxins. <i>Toxicon</i> , 2009 , 54, 675	2.8	3
67	Can falls be prevented in Parkinson's disease?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007 , 78, 661	5.5	3
66	Apomorphine and levodopa challenge in patients with a focal midbrain lesion. <i>Movement Disorders</i> , 1999 , 14, 269-75	7	3

65	Boxer disqualified for taking selegiline. <i>Lancet, The</i> , 1995 , 346, 647	40	3
64	Neuropeptides in dopamine-containing regions of the brain. <i>Italian Journal of Neurological Sciences</i> , 1984 , 5, 391-404		3
63	Motor and Sensory Features of Cervical Dystonia Subtypes: Data From the Italian Dystonia Registry. <i>Frontiers in Neurology</i> , 2020 , 11, 906	4.1	3
62	Trigeminal features in COVID-19 patients with smell impairment. <i>International Forum of Allergy and Rhinology</i> , 2021 , 11, 1253-1255	6.3	3
61	Distinguishing Clinical Features of Hyperkinetic Disorders1-14		3
60	DYT13, a novel primary torsion dystonia locus, maps to chromosome 1p36.13B6.32 in an Italian family with cranial-cervical or upper limb onset 2001 , 49, 362		3
59	Cholinergic-Monoaminergic Interactions in Selected Regions of the Brain: Histochemical and Pharmacologic Analyses. <i>Advances in Behavioral Biology</i> , 1981 , 723-738		3
58	Clinical genetic study of familial Parkinson's disease in Italy. <i>Advances in Neurology</i> , 1999 , 80, 181-6		3
57	Dystonia in parkinsonian syndromes. <i>Advances in Neurology</i> , 2003 , 91, 351-60		3
56	Early versus delayed bilateral subthalamic deep brain stimulation for Parkinson's disease: need for long-term clinical trials. <i>Movement Disorders</i> , 2011 , 26, 1370; author reply 1371	7	2
55	The current model of basal ganglia organization: a clinician's view. <i>Movement Disorders</i> , 1998 , 13, 980-1	7	2
54	The current status and use of botulinum toxins. <i>European Journal of Neurology</i> , 2001 , 8, 3-7	6	2
53	Functional impairment of nigrostriatal neurons progresses following withdrawal of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. <i>Neuroscience</i> , 1996 , 75, 1185-91	3.9	2
52	Correlation of cardiovascular autonomic function tests, magnetic resonance brain imaging and clinical features in suspect cases of multiple system atrophy. <i>Functional Neurology</i> , 1991 , 6, 269-73	2.2	2
51	Chronic administration of MPTP to marmosets. <i>Advances in Neurology</i> , 1990 , 53, 239-44		2
50	Coronary embolization from aortic valve fibroelastoma. <i>Clinical Case Reports (discontinued)</i> , 2020 , 8, 1610-1612		2
49	Worldwide barriers to genetic testing for movement disorders. <i>European Journal of Neurology</i> , 2021 , 28, 1901-1909	6	2
48	Dystonia Management: What to Expect From the Future? The Perspectives of Patients and Clinicians Within DystoniaNet Europe. <i>Frontiers in Neurology</i> , 2021 , 12, 646841	4.1	2

47	Impulse control behavior in GBA-mutated parkinsonian patients. <i>Journal of the Neurological Sciences</i> , 2021 , 421, 117291	3.2	2
46	Prefrontal Cortical Stimulation in Tourette Disorder: Proof-of-concept Clinical and Neuroimaging Study. <i>Movement Disorders Clinical Practice</i> , 2018 , 5, 499-505	2.2	2
45	Functional gait disorders: Demographic and clinical correlations. <i>Parkinsonism and Related Disorders</i> , 2021 , 91, 32-36	3.6	2
44	Primary Dystonias 113-134		2
43	Implementation of the Current Dystonia Classification from 2013 to 2018. <i>Movement Disorders Clinical Practice</i> , 2019 , 6, 250-253	2.2	1
42	Management of sleep disorders in Parkinson's disease 151-161		1
41	A 52-Year-Old Man with Myoclonic Jerks. <i>Brain Pathology</i> , 2016 , 26, 291-2	6	1
40	Other Tremors 2012 , 95-111		1
39	Dystonic Tremor 2013 , 203-218		1
38	Diagnostic issues in childhood and adult dystonia. <i>Expert Opinion on Medical Diagnostics</i> , 2011 , 5, 483-500		1
37	Botulinum Neurotoxin in Tremors, Tics, Hemifacial Spasm, Spasmodic Dysphonia, and Stuttering 2009 , 112-130		1
36	Cutaneous herpes zoster and implantable pulse generator. <i>Neuromodulation</i> , 2010 , 13, 99-101	3.1	1
35	Transient alternating hemichorea as presenting sign of progressive supranuclear palsy. <i>Italian Journal of Neurological Sciences</i> , 1991 , 12, 99-101		1
34	Attentional networks in Parkinson's disease. <i>Behavioural Neurology</i> , 2013 , 27, 495-500	3	1
33	Amyotrophic onset in GCH1 dopa-responsive dystonia. <i>Iranian Journal of Neurology</i> , 2019 , 18, 181-183	0.6	1
32	Initial bromocriptine did not change mortality in early, mild Parkinson disease. <i>Annals of Internal Medicine</i> , 2002 , 136, 109	8	1
31	Clinical Use of Botulinum Neurotoxin: Neuromuscular Disorders 2014 , 51-93		1
30	Neuropsychiatric Disturbances in Dystonia. <i>Neuropsychiatric Symptoms of Neurological Disease</i> , 2015 , 171-199		1

29	Spread of segmental/multifocal idiopathic adult-onset dystonia to a third body site. <i>Parkinsonism and Related Disorders</i> , 2021 , 87, 70-74	3.6	1
28	Parkinsonism and dysautonomia: Multiple system atrophy?. <i>Parkinsonism and Related Disorders</i> , 2020 , 77, 146-149	3.6	1
27	Neuroimaging in idiopathic adult-onset focal dystonia. <i>Neurological Sciences</i> , 2021 , 42, 2947-2950	3.5	1
26	Chronic Administration of 1-Methyl-4-Phenyl-1,2,3,6- Tetrahydropyridine to Marmosets. <i>Advances in Behavioral Biology</i> , 1991 , 523-531		1
25	Nanotechnology and vascular neurosurgery: an in vivo experimental study on microvessels repair using laser photoactivation of a nanostructured hyaluronan solder. <i>Journal of Biological Regulators and Homeostatic Agents</i> , 2012 , 26, 447-56	0.7	1
24	Development of a patient journey map for people living with cervical dystonia.. <i>Orphanet Journal of Rare Diseases</i> , 2022 , 17, 130	4.2	1
23	Reply: dystonia after severe head injuries. <i>Movement Disorders</i> , 2014 , 29, 578-9	7	0
22	Standard strategies for diagnosis and treatment of patients with newly diagnosed Parkinson disease: ITALY. <i>Neurology: Clinical Practice</i> , 2013 , 3, 476-477	1.7	0
21	Clinical Features of Dystonia and European Guidelines for Diagnosis and Treatment 2007 , 3-9		0
20	Adult diagnosis of Cockayne syndrome. <i>Neurology</i> , 2019 , 93, 854-855	6.5	0
19	Sudden Onset, Fixed Dystonia and Acute Peripheral Trauma as Diagnostic Clues for Functional Dystonia. <i>Movement Disorders Clinical Practice</i> , 2021 , 8, 1107-1111	2.2	0
18	Tics and Tremors 2015 , 743-750		
17	Hyperkinesia, dystonia, and tics 291-300		
16	Reply to Dr Michaud et'al. <i>European Journal of Neurology</i> , 2015 , 22, e78	6	
15	Acquired Chorea 2012 , 175-187		
14	Inherited Myoclonus Syndromes 2012 , 207-220		
13	Pathophysiology and Molecular Pathology of Dystonia and Tics 2012 , 15-25		
12	Response to letter by Dr Neil Murray. <i>European Journal of Neurology</i> , 2011 , 18, e62-e62	6	

- 11 Clinical Trials of Botulinum Toxin in Adult Spasticity **2009**, 148-158
- 10 Hypersalivation 201-228
- 9 Suprasegmental control of vegetative nervous system. *Functional Neurology*, **1987**, 2, 407-16 2.2
- 8 Diagnosis and Treatment of Primary (Idiopathic) Dystonia 191-206
- 7 Other Jerks and Startles 236-256
- 6 Dyskinesias in Parkinsonian Syndromes 297-310
- 5 Patient-centred management of Parkinson's disease. *Lancet Neurology*, **2020**, 19, 888-889 24.1
- 4 Management algorithm for BoNT injections with electromyography and ultrasound guidance in cervical dystonia. *Toxicon*, **2018**, 156, S14-S15 2.8
- 3 New delivery systems for antiparkinsonian drugs. *Advances in Neurology*, **1999**, 80, 549-54
- 2 Review: several drugs are efficacious for symptomatic treatment of Parkinson disease. *ACP Journal Club*, **2003**, 138, 14
- 1 Review: Several drugs are efficacious for symptomatic treatment of Parkinson disease. *ACP Journal Club*, **2003**, 138, 14